Safety of AZD1222 COVID-19 vaccine and low Incidence of SARS-CoV-2 infection in Botswana following ChAdOx1(AZD1222) vaccination: A single-arm open-label interventional study – final study results

• Published in: IJID regions 2024-03, Vol.10, p.35-43
• Main Authors: Makhema, Joseph, Shava, Emily, Izu, Alane, Gaolathe, Tendani, Kuate, Lesego, Walker, Adam, Carty, Lucy, Georgiou, Panayiotis, Kgathi, Coulson, Choga, Wonderful T., Sekoto, Tumalano, Seonyatseng, Ngozana, Mogashoa, Tuelo, Maphorisa, Comfort N., Mohammed, Terence, Ntalabgwe, Tshenolo, Frank, Tshepho T., Matlhaku, Boitumelo, Diphoko, Ame, Phindela, Thandie, Kaunda, Agripa, Kgari, Poloko, Kanyakula, Thomas, Palalani, Gape, Phakedi, Isabella, Mmalane, Mompati, Taylor, Sylvia, Moyo, Sikhulile
• Format: Article
• Language: English
• Subjects: Antibody responses; AstraZeneca; AZD 1222; Botswana; COVID-19 vaccination; Original Report
• ISSN: 2772-7076; 2772-7076
• DOI: 10.1016/j.ijregi.2023.11.002

•We confirmed the safety of the AZD1222 COVID-19 vaccine in Botswana.•Low incidence of symptomatic COVID-19 infection following two doses of AZD1222.•AZD1222 was safe and effective. No differences in immune responses by HIV status.•Adverse events were higher in participants with prior COVID-19 infection.•We observed higher antibody responses in participants with prior COVID-19 exposure. We report the final analysis of the single-arm open-label study evaluating the safety and COVID-19 incidence after AZD1222 vaccination in Botswana conducted between September 2021 and August 2022. The study included three groups of adults (>18 years), homologous AZD1222 primary series and booster (AZ2), heterologous primary series with one dose AZD1222, and AZD1222 booster (HPS), and primary series other than AZD1222 and AZD1222 booster (OPS). We compared the incidence of AEs in participants with and without prior COVID-19 infection using an exact test for rate ratios. Among 10,894 participants, 9192 (84.4%) were enrolled at first vaccine dose, 521 (4.8%) at second vaccine, and 1181 (10.8%) at the booster vaccine. Of 10,855 included in the full analysis set, 1700 received one dose of AZD1222; 5377 received two doses; 98 received a heterologous series including one AZD1222 and a booster; 30 in the HPS group; 1058 in the OPS group; and 2592 in the AZ2 group. No laboratory-confirmed COVID-19 hospitalizations or deaths were reported. The incidence of laboratory-confirmed symptomatic COVID infection for the AZ2 group was 6.22 (95% confidence interval: 2.51-12.78) per 1000 participant-years (1000-PY) and 3.5 (95% confidence interval: 0.42-12.57) per 1000-PY for AZ2+booster group. Most adverse events were mild, with higher incidence in participants with prior COVID-19 infection. Individuals with prior COVID-19 exposure exhibited higher binding antibody responses. No differences in outcomes were observed by HIV status. AZD1222 is safe, effective, and immunogenic for people living with and without HIV.